TY - JOUR
T1 - In utero and lactational exposure to 2,3,7,8-tetrachlorodibenzo-p- dioxin (TCDD) induces genital dysmorphogenesis in the female rat
AU - Flaws, Jodi A.
AU - Sommer, Rebecca J.
AU - Silbergeld, Ellen K.
AU - Peterson, Richard E.
AU - Hirshfield, Anne N.
N1 - Funding Information:
The authors thank Andrea M. DeSanti for her expert technical assistance. J.A.F. and R.J.S. contributed equally to this work. J.A.F. is supported by a Wyeth Ayerst Postdoctoral Fellowship in Clinical Epidemiologya nd Women's Health. R.J.S. is supported by a Samuel C. Johnson Distinguished Fellowship for Graduate Research. This work was supported by AG13844, the Heinz Family Foundation, and ESO1332.
PY - 1997/12
Y1 - 1997/12
N2 - Recently, Gray and Ostby (Toxicol. Appl. Pharmacol. 133, 285294, 1995) reported that in utero and lactational TCDD exposure causes striking abnormalities in the rat female reproductive system, including reduced fecundity and vaginal threads. The mechanism by which TCDD induces such abnormalities is unknown. Thus, we sought to determine: (1) whether TCDD reduced fecundity by destroying ovarian follicles and (2) whether the vaginal threads resulted from a TCDD-induced developmental defect during embryogenesis or abnormal vaginal opening at puberty. Pregnant Holtzman rats were treated with 1.0 μg TCDD/kg or vehicle by a single oral dose on gestation day (GD) 11, 15, or 18. Female offspring were monitored for vaginal opening and terminated on postnatal days 2, 21, and 42. The reproductive tract was removed and evaluated for structural abnormalities. The number of primordial follicles also was determined for each ovary. TCDD exposure on GD 11, 15, or 18 did not change the day of vaginal opening, affect ovarian morphology, or reduce the number of primordial follicles. However, this exposure induced the cleft clitoris and vaginal thread originally described by Gray and Ostby (1995) in approximately 55-96% and 36-44% of the litters in our study, respectively. Histologically the thread presented as a thick cord of mesenchyme surrounded by epithelial cells. This defect was clearly visible in histological sections at birth and was noted in the closed vaginas of prepubertal animals. These data suggest that in utero and lactational exposure to TCDD does not reduce the size of the primordial follicle pool; however, it induces developmental abnormalities in the vaginal canal.
AB - Recently, Gray and Ostby (Toxicol. Appl. Pharmacol. 133, 285294, 1995) reported that in utero and lactational TCDD exposure causes striking abnormalities in the rat female reproductive system, including reduced fecundity and vaginal threads. The mechanism by which TCDD induces such abnormalities is unknown. Thus, we sought to determine: (1) whether TCDD reduced fecundity by destroying ovarian follicles and (2) whether the vaginal threads resulted from a TCDD-induced developmental defect during embryogenesis or abnormal vaginal opening at puberty. Pregnant Holtzman rats were treated with 1.0 μg TCDD/kg or vehicle by a single oral dose on gestation day (GD) 11, 15, or 18. Female offspring were monitored for vaginal opening and terminated on postnatal days 2, 21, and 42. The reproductive tract was removed and evaluated for structural abnormalities. The number of primordial follicles also was determined for each ovary. TCDD exposure on GD 11, 15, or 18 did not change the day of vaginal opening, affect ovarian morphology, or reduce the number of primordial follicles. However, this exposure induced the cleft clitoris and vaginal thread originally described by Gray and Ostby (1995) in approximately 55-96% and 36-44% of the litters in our study, respectively. Histologically the thread presented as a thick cord of mesenchyme surrounded by epithelial cells. This defect was clearly visible in histological sections at birth and was noted in the closed vaginas of prepubertal animals. These data suggest that in utero and lactational exposure to TCDD does not reduce the size of the primordial follicle pool; however, it induces developmental abnormalities in the vaginal canal.
UR - http://www.scopus.com/inward/record.url?scp=0031422582&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031422582&partnerID=8YFLogxK
U2 - 10.1006/taap.1997.8295
DO - 10.1006/taap.1997.8295
M3 - Article
C2 - 9439730
AN - SCOPUS:0031422582
SN - 0041-008X
VL - 147
SP - 351
EP - 362
JO - Toxicology and Applied Pharmacology
JF - Toxicology and Applied Pharmacology
IS - 2
ER -